person · Reporting owner

Horn Margaret A

Disclosed activity across 2 companies

Tapewire entity: 37201
SEC CIK: 0001294192

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Revolution Medicines, Inc.RVMD · Entity 606	Chief Operating Officer	September 16, 2026	September 18, 2026
SANGAMO THERAPEUTICS, INCSGMO · Entity 7038	Director	June 12, 2025	June 16, 2025

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Revolution Medicines, Inc.

Report date September 16, 2026 · Filed September 18, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	154,571	Reported balance After 2026-09-16 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-09-16 · Sale · Disposed 76 · Balance 154,571 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Common StockSEC Table I · non-derivative	Direct	149,680	Reported balance After 2026-09-16 transaction · row 2 Account or security details depend on footnotes; rows are not merged. 1 source row Row 2 · 2026-09-16 · Sale · Disposed 4,891 · Balance 149,680 F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units. F3: Includes 56,713 restricted stock units.

Filing footnotes · ownership attribution and instrument terms

F1: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units.

F2: The transaction was executed in multiple trades at prices ranging from $195.00 to $195.03, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.

F3: Includes 56,713 restricted stock units.

SANGAMO THERAPEUTICS, INC

Report date June 12, 2025 · Filed June 16, 2025

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	82,650	Reported balance After 2025-06-12 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2025-06-12 · Grant · Acquired 25,000 · Balance 82,650 F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.50 · Expires 2035-06-11	Direct	50,000	Reported balance After 2025-06-12 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-06-12 · Grant · Acquired 50,000 · Balance 50,000 F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Filing footnotes · ownership attribution and instrument terms

F1: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 12, 2026 or (b) the day prior to the 2026 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP.

F2: Includes 6,251 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in one final installment on December 15, 2025.

F3: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
September 16, 2024 Filed Sep 18, 2024 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	4,331	$44.19	$191,366.53	Disclosure SEC source: 0001610717-24-000487 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,320 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · balance_after: Includes 77,300 RSUs. Read SEC document
June 17, 2024 Filed Jun 20, 2024 20:12 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	4,415	$37.39	$165,063.61	Disclosure SEC source: 0001610717-24-000350 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 136,651 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of restricted stock units ("RSUs") after July 15, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $37.3868 to $37.3875, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 1,513 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2024. F4 · balance_after: Includes 85,726 RSUs. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:24 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	50,000	$0.00 Strike: $0.57	$0.00	Disclosure SEC source: 0001415889-24-015755 · form4-06062024_080623.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2034-06-03 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
June 04, 2024 Filed Jun 6, 2024 20:24 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	25,000	$0.00	$0.00	Disclosure SEC source: 0001415889-24-015755 · form4-06062024_080623.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,650 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 4, 2025 or (b) the day prior to the 2025 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 12,500 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in two equal annual installments of 6,250 shares on each of December 15, 2024 and 2025. Read SEC document
March 18, 2024 Filed Mar 20, 2024 20:44 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,914	$31.58	$92,033.44	Disclosure SEC source: 0001610717-24-000172 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 139,553 F1 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023. F2 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F3 · balance_after: Includes 94,150 RSUs. Read SEC document
March 12, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	7,936	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000160 · form4.xml · derivative · entry 6 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,631 Underlying: Common Stock · 7,936 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
March 12, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	7,936	$34.07	$270,345.40	Disclosure SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,467 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $34.00 to $34.14, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 100,013 restricted stock units. Read SEC document
March 12, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	7,936	$4.09	$32,458.24	Disclosure SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 150,403 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 100,013 restricted stock units. Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	15,735	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-24-000160 · form4.xml · derivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 52,567 Underlying: Common Stock · 15,735 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	15,735	$34.02	$535,306.27	Disclosure SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 142,467 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $34.00 to $34.11, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 100,013 restricted stock units. Read SEC document
March 11, 2024 Filed Mar 13, 2024 20:32 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	15,735	$4.09	$64,356.15	Disclosure SEC source: 0001610717-24-000160 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 158,202 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 100,013 restricted stock units. Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:55 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	143,500	$0.00 Strike: $29.80	$0.00	Disclosure SEC source: 0001610717-24-000134 · form4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 143,500 Underlying: Common Stock · 143,500 shares Expires 2034-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2024 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2024 Filed Mar 5, 2024 21:55 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	41,000	$0.00	$0.00	Disclosure SEC source: 0001610717-24-000134 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,467 F1 · balance_after: Includes 100,013 restricted stock units. Read SEC document
December 18, 2023 Filed Dec 20, 2023 00:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,993	$25.90	$77,524.09	Disclosure SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,467 F4 · kind: Transaction made pursuant to a Rule 10b5-1 instruction letter adopted on May 31, 2023 to satisfy the Reporting Person's tax withholding obligation upon the vesting of RSUs after July 15, 2023. F5 · shares: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F6 · price: This transaction was executed in multiple trades in prices ranging from $25.9016 to $25.9219, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 59,013 restricted stock units ("RSUs"). Read SEC document
December 15, 2023 Filed Dec 20, 2023 00:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000407 · form4.xml · derivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 68,302 Underlying: Common Stock · 5,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
December 15, 2023 Filed Dec 20, 2023 00:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$26.64	$133,183.00	Disclosure SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,460 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $26.04 to $26.93, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 59,013 restricted stock units ("RSUs"). Read SEC document
December 15, 2023 Filed Dec 20, 2023 00:30 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	5,000	$4.09	$20,450.00	Disclosure SEC source: 0001610717-23-000407 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 59,013 restricted stock units ("RSUs"). Read SEC document
December 06, 2023 Filed Dec 8, 2023 21:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000393 · form4.xml · derivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 73,302 Underlying: Common Stock · 5,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
December 06, 2023 Filed Dec 8, 2023 21:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$25.00	$125,000.00	Disclosure SEC source: 0001610717-23-000393 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,460 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
December 06, 2023 Filed Dec 8, 2023 21:08 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	5,000	$4.09	$20,450.00	Disclosure SEC source: 0001610717-23-000393 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 25, 2023 Filed Oct 25, 2023 22:20 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	7,500	$0.00 Strike: $0.54	$0.00	Disclosure SEC source: 0001610717-23-000315 · form4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,941 Underlying: Common Stock · 7,500 shares Expires 2028-02-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document
October 25, 2023 Filed Oct 25, 2023 22:20 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	7,500	$0.54	$4,050.00	Disclosure SEC source: 0001610717-23-000315 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,460 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	25,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000310 · form4.xml · derivative · entry 7 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 78,302 Underlying: Common Stock · 25,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	400	$35.00	$13,998.00	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 6 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,960 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F6 · price: This transaction was executed in multiple trades in prices ranging from $34.76 to $35.18, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	23,200	$34.02	$789,231.52	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 5 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 97,360 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F5 · price: This transaction was executed in multiple trades in prices ranging from $33.73 to $34.66, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	800	$33.23	$26,583.04	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 120,560 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $32.72 to $33.61, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	500	$31.96	$15,978.00	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,360 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $31.41 to $32.40, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	100	$30.15	$3,015.00	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,860 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
October 16, 2023 Filed Oct 18, 2023 20:23 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	25,000	$4.09	$102,250.00	Disclosure SEC source: 0001610717-23-000310 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 121,960 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 64,875 restricted stock units. Read SEC document
September 18, 2023 Filed Sep 19, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,514	$31.31	$78,714.60	Disclosure SEC source: 0001610717-23-000288 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 96,960 F4 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the RSUs award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F5 · price: This transaction was executed in multiple trades in prices ranging from $31.1010 to $31.3108, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units ("RSUs"). Read SEC document
September 15, 2023 Filed Sep 19, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000288 · form4.xml · derivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 103,302 Underlying: Common Stock · 5,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
September 15, 2023 Filed Sep 19, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	5,000	$32.08	$160,408.50	Disclosure SEC source: 0001610717-23-000288 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,474 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $31.60 to $32.51, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 64,875 restricted stock units ("RSUs"). Read SEC document
September 15, 2023 Filed Sep 19, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	5,000	$4.09	$20,450.00	Disclosure SEC source: 0001610717-23-000288 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 64,875 restricted stock units ("RSUs"). Read SEC document
August 31, 2023 Filed Sep 1, 2023 20:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	10,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000252 · form4.xml · derivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 108,302 Underlying: Common Stock · 10,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
August 31, 2023 Filed Sep 1, 2023 20:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	10,000	$34.05	$340,458.00	Disclosure SEC source: 0001610717-23-000252 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,474 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $34.00 to $34.08, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 70,738 restricted stock units. Read SEC document
August 31, 2023 Filed Sep 1, 2023 20:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	10,000	$4.09	$40,900.00	Disclosure SEC source: 0001610717-23-000252 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 109,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 70,738 restricted stock units. Read SEC document
August 15, 2023 Filed Aug 17, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionStock Option (Right to Buy) · Derivative	5,000	$0.00 Strike: $4.09	$0.00	Disclosure SEC source: 0001610717-23-000229 · form4.xml · derivative · entry 4 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 118,302 Underlying: Common Stock · 5,000 shares Expires 2029-03-12 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. Read SEC document
August 15, 2023 Filed Aug 17, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,915	$30.80	$58,980.66	Disclosure SEC source: 0001610717-23-000229 · form4.xml · nonDerivative · entry 3 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 99,474 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F4 · price: This transaction was executed in multiple trades in prices ranging from $30.69 to $30.91, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 70,738 restricted stock units. Read SEC document
August 15, 2023 Filed Aug 17, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	3,085	$30.36	$93,651.65	Disclosure SEC source: 0001610717-23-000229 · form4.xml · nonDerivative · entry 2 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 101,389 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F3 · price: This transaction was executed in multiple trades in prices ranging from $29.68 to $30.67, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F2 · balance_after: Includes 70,738 restricted stock units. Read SEC document
August 15, 2023 Filed Aug 17, 2023 20:17 UTC	Revolution Medicines, Inc. RVMD · Entity 606	Exercise / conversionCommon Stock	5,000	$4.09	$20,450.00	Disclosure SEC source: 0001610717-23-000229 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 104,474 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 29, 2023. F2 · balance_after: Includes 70,738 restricted stock units. Read SEC document
June 20, 2023 Filed Jun 22, 2023 20:26 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	2,102	$24.89	$52,320.88	Disclosure SEC source: 0001610717-23-000194 · form4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,474 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · balance_after: Includes 1,514 shares acquired under the Issuer's Employee Stock Purchase Plan on May 31, 2023. F3 · balance_after: Includes 70,738 RSUs. Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:48 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	27,750	$0.00 Strike: $1.11	$0.00	Disclosure SEC source: 0001209191-23-034392 · doc4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,750 Underlying: Common Stock · 27,750 shares Expires 2033-05-31 F3 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 12 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
June 01, 2023 Filed Jun 5, 2023 20:48 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	13,900	$0.00	$0.00	Disclosure SEC source: 0001209191-23-034392 · doc4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 32,650 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit ("RSU") grant that will fully vest on the earlier of (a) June 1, 2024 or (b) the day prior to the 2024 annual meeting of stockholders, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")) through such date and subject to acceleration as provided in the 2018 EIP. F2 · balance_after: Includes 18,750 shares subject to the Reporting Person's December 15, 2022 RSU grant that will vest in three equal annual installments 0f 6,250 shares on each of December 15, 2023, 2024 and 2025. Read SEC document
March 17, 2023 Filed Mar 22, 2023 00:33 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,230	$21.78	$26,789.40	Disclosure SEC source: 0000899243-23-009377 · doc4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 100,062 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $21.4115 to $21.784581, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 76,600 RSUs. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantStock Option (Right to Buy) · Derivative	140,000	$0.00 Strike: $26.50	$0.00	Disclosure SEC source: 0001567619-23-004352 · doc1.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-02-28 F2 · derivative.exercise_date: One forty-eighth (1/48th) of the shares initially subject to the option will vest on each monthly anniversary measured from March 1, 2023 (the "Vesting Commencement Date"), so that 100% of the shares subject to the option will be fully vested and exercisable as of the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service through each vesting date. Read SEC document
March 01, 2023 Filed Mar 3, 2023 21:16 UTC	Revolution Medicines, Inc. RVMD · Entity 606	GrantCommon Stock	40,000	$0.00	$0.00	Disclosure SEC source: 0001567619-23-004352 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 101,292 F1 · balance_after: Includes 79,963 restricted stock units. Read SEC document
December 19, 2022 Filed Dec 21, 2022 21:05 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	1,220	$22.94	$27,985.46	Disclosure SEC source: 0001567619-22-021926 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,292 F1 · kind: Pursuant to an automatic sell-to-cover imposed by the terms of the restricted stock units ("RSUs") award, the shares were sold following the vesting of the RSUs solely to cover applicable withholding taxes. F2 · price: This transaction was executed in multiple trades in prices ranging from $22.4701 to $22.96, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · balance_after: Includes 39,963 RSUs. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:45 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantStock Option (Right to Buy) · Derivative	37,500	$0.00 Strike: $3.30	$0.00	Disclosure SEC source: 0001209191-22-061951 · doc4.xml · derivative · entry 2 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,500 Underlying: Common Stock · 37,500 shares Expires 2032-12-14 F2 · derivative.exercise_date: The option is immediately exercisable in full, but any unvested shares that are purchased under the option are subject to certain repurchase rights by the Issuer upon cessation of the Reporting Person's Continuous Service (as defined in the 2018 EIP). The shares subject to the option will vest in 36 successive equal monthly installments following the grant date, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
December 15, 2022 Filed Dec 19, 2022 21:45 UTC	SANGAMO THERAPEUTICS, INC SGMO · Entity 7038	GrantCommon Stock	18,750	$0.00	$0.00	Disclosure SEC source: 0001209191-22-061951 · doc4.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 F1 · shares: Represents shares of common stock issuable upon settlement of a restricted stock unit grant that will vest in three equal annual installments measured from the grant date, subject to the Reporting Person's Continuous Service (as defined in the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP")), through each such date and subject to acceleration as provided in the 2018 EIP. Read SEC document
November 07, 2022 Filed Nov 9, 2022 21:13 UTC	Revolution Medicines, Inc. RVMD · Entity 606	SaleCommon Stock	17,767	$20.15	$358,069.01	Disclosure SEC source: 0001567619-22-019381 · doc1.xml · nonDerivative · entry 1 Horn Margaret A · CIK 0001294192 · Chief Operating Officer 10b5-1 filing: Not disclosed Ownership: Indirect · Trust Disclosed balance after: 0 F1 · kind: Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person. F2 · price: This transaction was executed in multiple trades in prices ranging from $20.00 to $20.62, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. F3 · ownership.nature: Held by Margaret A. Horn Revocable Living Trust. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.